Inicio>>ACP-5862

ACP-5862

Catalog No.GC39541

ACP-5862 es un importante metabolito de acalabrutinib con anillo abierto de pirrolidina, activo y circulante, con una IC50 de 5,0 nM para la tirosina quinasa de Bruton (BTK). ACP‐5862 es un inactivador débil dependiente del tiempo de CYP3A4 y CYP2C8. Acalabrutinib es un inhibidor de BTK altamente selectivo, irreversible y activo por vÍa oral, con una IC50 de 3 nM y una EC50 de 8 nM.

Products are for research use only. Not for human use. We do not sell to patients.

ACP-5862 Chemical Structure

Cas No.: 2230757-47-6

Tamaño Precio Disponibilidad Cantidad
10mM (in 1mL DMSO)
639,00 $
Disponible
1mg
278,00 $
Disponible
5mg
603,00 $
Disponible
10mg
881,00 $
Disponible
50mg
2.596,00 $
Disponible

Tel:(909) 407-4943 Email: sales@glpbio.com

Reseñas de cliente

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

ACP-5862 is a major active, circulating, pyrrolidine ring-opened metabolite of Acalabrutinib with an IC50 of 5.0 nM for Bruton tyrosine kinase (BTK)[1]. Acalabrutinib is an orally active, irreversible, and highly selective BTK inhibitor, with an IC50 of 3 nM and EC50 of 8 nM[2].

[1]. Podoll T, et al. Bioavailability, Biotransformation, and Excretion of the Covalent Bruton Tyrosine Kinase Inhibitor Acalabrutinib in Rats, Dogs, and Humans. Drug Metab Dispos. 2019 Feb;47(2):145-154. [2]. Herman SE, et al. The Bruton's tyrosine kinase (BTK) inhibitor acalabrutinib demonstrates potent on-target effects and efficacy in two mouse models of chronic lymphocytic leukemia. Clin Cancer Res. 2016 Nov 30

Reseñas

Review for ACP-5862

Average Rating: 5 ★★★★★ (Based on Reviews and 31 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for ACP-5862

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.